Exact Mass: 550.2625282

Exact Mass Matches: 550.2625282

Found 135 metabolites which its exact mass value is equals to given mass value 550.2625282, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Manumycin A

(2E,4E,6R)-N-[(1S,5S,6R)-5-hydroxy-5-[(1E,3E,5E)-7-[(2-hydroxy-5-oxo-cyclopenten-1-yl)amino]-7-oxo-hepta-1,3,5-trienyl]-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]-2,4,6-trimethyl-deca-2,4-dienamide

C31H38N2O7 (550.2678877999999)


A polyketide with formula C31H38N2O7 initially isolated from Streptomyces parvulus as a result of a random screening program for farnesyl transferase (FTase) inhibitors. It is a natural product that exhibits anticancer and antibiotic properties. Manumycin A is a polyketide with formula C31H38N2O7 initially isolated from Streptomyces parvulus as a result of a random screening program for farnesyl transferase (FTase) inhibitors. It is a natural product that exhibits anticancer and antibiotic properties. It has a role as an EC 1.8.1.9 (thioredoxin reductase) inhibitor, an EC 2.5.1.58 (protein farnesyltransferase) inhibitor, an antineoplastic agent, an apoptosis inducer, an antimicrobial agent, a bacterial metabolite, an antiatherosclerotic agent and a marine metabolite. It is a polyketide, an enamide, an epoxide, an organic heterobicyclic compound, a secondary carboxamide and a tertiary alcohol. Manumycin A is a natural product found in Streptomyces, Streptomyces griseoaurantiacus, and Streptomyces parvulus D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents D004791 - Enzyme Inhibitors

   

Manumycin A

N-(5-Hydroxy-5-{6-[(2-hydroxy-5-oxocyclopent-1-en-1-yl)-C-hydroxycarbonimidoyl]hexa-1,3,5-trien-1-yl}-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl)-2,4,6-trimethyldeca-2,4-dienimidate

C31H38N2O7 (550.2678877999999)


   

PA(2:0/PGF2alpha)

[(2R)-3-(acetyloxy)-2-{[(5E)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]hept-5-enoyl]oxy}propoxy]phosphonic acid

C25H43O11P (550.2542857999999)


PA(2:0/PGF2alpha) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/PGF2alpha), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Prostaglandin F2alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGF2alpha/2:0)

[(2R)-2-(acetyloxy)-3-{[(5E)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]hept-5-enoyl]oxy}propoxy]phosphonic acid

C25H43O11P (550.2542857999999)


PA(PGF2alpha/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGF2alpha/2:0), in particular, consists of one chain of one Prostaglandin F2alpha at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(2:0/PGE1)

[(2R)-3-(acetyloxy)-2-({7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]heptanoyl}oxy)propoxy]phosphonic acid

C25H43O11P (550.2542857999999)


PA(2:0/PGE1) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/PGE1), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Prostaglandin E1 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGE1/2:0)

[(2R)-2-(acetyloxy)-3-({7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]heptanoyl}oxy)propoxy]phosphonic acid

C25H43O11P (550.2542857999999)


PA(PGE1/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGE1/2:0), in particular, consists of one chain of one Prostaglandin E1 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(2:0/PGD1)

[(2R)-3-(acetyloxy)-2-({7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]heptanoyl}oxy)propoxy]phosphonic acid

C25H43O11P (550.2542857999999)


PA(2:0/PGD1) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/PGD1), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Prostaglandin D1 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGD1/2:0)

[(2R)-2-(acetyloxy)-3-({7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]heptanoyl}oxy)propoxy]phosphonic acid

C25H43O11P (550.2542857999999)


PA(PGD1/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGD1/2:0), in particular, consists of one chain of one Prostaglandin D1 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

Tigloylseneganolide A

Tigloylseneganolide A

C32H38O8 (550.2566548)


   
   
   

16-oxo-heteroclitalactone H|heteroclitalactone K

16-oxo-heteroclitalactone H|heteroclitalactone K

C32H38O8 (550.2566548)


   

17-hydroxyingenol 17-benzoate-20-angelate

17-hydroxyingenol 17-benzoate-20-angelate

C32H38O8 (550.2566548)


   

(3S,5R,6S,7E,9S)-megastigman-7-ene-5,6-epoxy-3,9-diol

(3S,5R,6S,7E,9S)-megastigman-7-ene-5,6-epoxy-3,9-diol

C25H42O13 (550.2625282)


   
   
   
   

1-O-cinnamoyl-17-defurano-17-oxosalannicacid methyl ester|17-defurano-17-oxoohchinin

1-O-cinnamoyl-17-defurano-17-oxosalannicacid methyl ester|17-defurano-17-oxoohchinin

C32H38O8 (550.2566548)


   

3-O-angeloyl-17-(benzoyloxy)ingenol|ingenol-3-angelate-17-benzoate

3-O-angeloyl-17-(benzoyloxy)ingenol|ingenol-3-angelate-17-benzoate

C32H38O8 (550.2566548)


   

5-O-angeloyl-17-O-benzoylingenol

5-O-angeloyl-17-O-benzoylingenol

C32H38O8 (550.2566548)


   
   
   

Ala Phe Gln Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-phenylpropanamido]-4-carbamoylbutanamido]-3-(1H-indol-3-yl)propanoic acid

C28H34N6O6 (550.2539704000001)


   

Ala Phe Trp Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-phenylpropanamido]-3-(1H-indol-3-yl)propanamido]-4-carbamoylbutanoic acid

C28H34N6O6 (550.2539704000001)


   

Ala Gln Phe Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-4-carbamoylbutanamido]-3-phenylpropanamido]-3-(1H-indol-3-yl)propanoic acid

C28H34N6O6 (550.2539704000001)


   

Ala Gln Trp Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-4-carbamoylbutanamido]-3-(1H-indol-3-yl)propanamido]-3-phenylpropanoic acid

C28H34N6O6 (550.2539704000001)


   

Ala Trp Phe Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-(1H-indol-3-yl)propanamido]-3-phenylpropanamido]-4-carbamoylbutanoic acid

C28H34N6O6 (550.2539704000001)


   

Ala Trp Gln Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-(1H-indol-3-yl)propanamido]-4-carbamoylbutanamido]-3-phenylpropanoic acid

C28H34N6O6 (550.2539704000001)


   

Phe Ala Gln Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]propanamido]-4-carbamoylbutanamido]-3-(1H-indol-3-yl)propanoic acid

C28H34N6O6 (550.2539704000001)


   

Phe Ala Trp Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]propanamido]-3-(1H-indol-3-yl)propanamido]-4-carbamoylbutanoic acid

C28H34N6O6 (550.2539704000001)


   

Phe Phe His Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-phenylpropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-hydroxybutanoic acid

C28H34N6O6 (550.2539704000001)


   

Phe Phe Thr His

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-phenylpropanamido]-3-hydroxybutanamido]-3-(1H-imidazol-4-yl)propanoic acid

C28H34N6O6 (550.2539704000001)


   

Phe His Phe Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-phenylpropanamido]-3-hydroxybutanoic acid

C28H34N6O6 (550.2539704000001)


   

Phe His Thr Phe

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-hydroxybutanamido]-3-phenylpropanoic acid

C28H34N6O6 (550.2539704000001)


   

Phe Gln Ala Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-4-carbamoylbutanamido]propanamido]-3-(1H-indol-3-yl)propanoic acid

C28H34N6O6 (550.2539704000001)


   

Phe Gln Trp Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-4-carbamoylbutanamido]-3-(1H-indol-3-yl)propanamido]propanoic acid

C28H34N6O6 (550.2539704000001)


   

Phe Thr Phe His

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-3-phenylpropanamido]-3-hydroxybutanamido]-3-phenylpropanamido]-3-(1H-imidazol-4-yl)propanoic acid

C28H34N6O6 (550.2539704000001)


   

Phe Thr His Phe

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-3-phenylpropanamido]-3-hydroxybutanamido]-3-(1H-imidazol-4-yl)propanamido]-3-phenylpropanoic acid

C28H34N6O6 (550.2539704000001)


   

Phe Trp Ala Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-(1H-indol-3-yl)propanamido]propanamido]-4-carbamoylbutanoic acid

C28H34N6O6 (550.2539704000001)


   

Phe Trp Gln Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-(1H-indol-3-yl)propanamido]-4-carbamoylbutanamido]propanoic acid

C28H34N6O6 (550.2539704000001)


   

His Phe Phe Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-phenylpropanamido]-3-phenylpropanamido]-3-hydroxybutanoic acid

C28H34N6O6 (550.2539704000001)


   

His Phe Thr Phe

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-phenylpropanamido]-3-hydroxybutanamido]-3-phenylpropanoic acid

C28H34N6O6 (550.2539704000001)


   

His Thr Phe Phe

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-hydroxybutanamido]-3-phenylpropanamido]-3-phenylpropanoic acid

C28H34N6O6 (550.2539704000001)


   

Lys Met Ser Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-4-(methylsulfanyl)butanamido]-3-hydroxypropanamido]-3-(1H-indol-3-yl)propanoic acid

C25H38N6O6S (550.2573408000001)


   

Lys Met Trp Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-4-(methylsulfanyl)butanamido]-3-(1H-indol-3-yl)propanamido]-3-hydroxypropanoic acid

C25H38N6O6S (550.2573408000001)


   

Lys Ser Met Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-hydroxypropanamido]-4-(methylsulfanyl)butanamido]-3-(1H-indol-3-yl)propanoic acid

C25H38N6O6S (550.2573408000001)


   

Lys Ser Trp Met

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-hydroxypropanamido]-3-(1H-indol-3-yl)propanamido]-4-(methylsulfanyl)butanoic acid

C25H38N6O6S (550.2573408000001)


   

Lys Trp Met Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-(1H-indol-3-yl)propanamido]-4-(methylsulfanyl)butanamido]-3-hydroxypropanoic acid

C25H38N6O6S (550.2573408000001)


   

Lys Trp Ser Met

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-(1H-indol-3-yl)propanamido]-3-hydroxypropanamido]-4-(methylsulfanyl)butanoic acid

C25H38N6O6S (550.2573408000001)


   

Met Lys Ser Trp

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]hexanamido]-3-hydroxypropanamido]-3-(1H-indol-3-yl)propanoic acid

C25H38N6O6S (550.2573408000001)


   

Met Lys Trp Ser

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]hexanamido]-3-(1H-indol-3-yl)propanamido]-3-hydroxypropanoic acid

C25H38N6O6S (550.2573408000001)


   

Met Ser Lys Trp

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-3-hydroxypropanamido]hexanamido]-3-(1H-indol-3-yl)propanoic acid

C25H38N6O6S (550.2573408000001)


   

Met Ser Trp Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-3-hydroxypropanamido]-3-(1H-indol-3-yl)propanamido]hexanoic acid

C25H38N6O6S (550.2573408000001)


   

Met Trp Lys Ser

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-3-(1H-indol-3-yl)propanamido]hexanamido]-3-hydroxypropanoic acid

C25H38N6O6S (550.2573408000001)


   

Met Trp Ser Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-3-(1H-indol-3-yl)propanamido]-3-hydroxypropanamido]hexanoic acid

C25H38N6O6S (550.2573408000001)


   

Gln Ala Phe Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]propanamido]-3-phenylpropanamido]-3-(1H-indol-3-yl)propanoic acid

C28H34N6O6 (550.2539704000001)


   

Gln Ala Trp Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]propanamido]-3-(1H-indol-3-yl)propanamido]-3-phenylpropanoic acid

C28H34N6O6 (550.2539704000001)


   

Gln Phe Ala Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-3-phenylpropanamido]propanamido]-3-(1H-indol-3-yl)propanoic acid

C28H34N6O6 (550.2539704000001)


   

Gln Phe Trp Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-3-phenylpropanamido]-3-(1H-indol-3-yl)propanamido]propanoic acid

C28H34N6O6 (550.2539704000001)


   

Gln Trp Ala Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-3-(1H-indol-3-yl)propanamido]propanamido]-3-phenylpropanoic acid

C28H34N6O6 (550.2539704000001)


   

Gln Trp Phe Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-3-(1H-indol-3-yl)propanamido]-3-phenylpropanamido]propanoic acid

C28H34N6O6 (550.2539704000001)


   

Ser Lys Met Trp

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-hydroxypropanamido]hexanamido]-4-(methylsulfanyl)butanamido]-3-(1H-indol-3-yl)propanoic acid

C25H38N6O6S (550.2573408000001)


   

Ser Lys Trp Met

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-hydroxypropanamido]hexanamido]-3-(1H-indol-3-yl)propanamido]-4-(methylsulfanyl)butanoic acid

C25H38N6O6S (550.2573408000001)


   

Ser Met Lys Trp

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-4-(methylsulfanyl)butanamido]hexanamido]-3-(1H-indol-3-yl)propanoic acid

C25H38N6O6S (550.2573408000001)


   

Ser Met Trp Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-4-(methylsulfanyl)butanamido]-3-(1H-indol-3-yl)propanamido]hexanoic acid

C25H38N6O6S (550.2573408000001)


   

Ser Trp Lys Met

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-(1H-indol-3-yl)propanamido]hexanamido]-4-(methylsulfanyl)butanoic acid

C25H38N6O6S (550.2573408000001)


   

Ser Trp Met Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-(1H-indol-3-yl)propanamido]-4-(methylsulfanyl)butanamido]hexanoic acid

C25H38N6O6S (550.2573408000001)


   

Thr Phe Phe His

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-phenylpropanamido]-3-phenylpropanamido]-3-(1H-imidazol-4-yl)propanoic acid

C28H34N6O6 (550.2539704000001)


   

Thr Phe His Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-phenylpropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-phenylpropanoic acid

C28H34N6O6 (550.2539704000001)


   

Thr His Phe Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-(1H-imidazol-4-yl)propanamido]-3-phenylpropanamido]-3-phenylpropanoic acid

C28H34N6O6 (550.2539704000001)


   

Trp Ala Phe Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]propanamido]-3-phenylpropanamido]-4-carbamoylbutanoic acid

C28H34N6O6 (550.2539704000001)


   

Trp Ala Gln Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]propanamido]-4-carbamoylbutanamido]-3-phenylpropanoic acid

C28H34N6O6 (550.2539704000001)


   

Trp Phe Ala Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-phenylpropanamido]propanamido]-4-carbamoylbutanoic acid

C28H34N6O6 (550.2539704000001)


   

Trp Phe Gln Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-phenylpropanamido]-4-carbamoylbutanamido]propanoic acid

C28H34N6O6 (550.2539704000001)


   

Trp Lys Met Ser

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]hexanamido]-4-(methylsulfanyl)butanamido]-3-hydroxypropanoic acid

C25H38N6O6S (550.2573408000001)


   

Trp Lys Ser Met

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]hexanamido]-3-hydroxypropanamido]-4-(methylsulfanyl)butanoic acid

C25H38N6O6S (550.2573408000001)


   

Trp Met Lys Ser

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-4-(methylsulfanyl)butanamido]hexanamido]-3-hydroxypropanoic acid

C25H38N6O6S (550.2573408000001)


   

Trp Met Ser Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-4-(methylsulfanyl)butanamido]-3-hydroxypropanamido]hexanoic acid

C25H38N6O6S (550.2573408000001)


   

Trp Gln Ala Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-4-carbamoylbutanamido]propanamido]-3-phenylpropanoic acid

C28H34N6O6 (550.2539704000001)


   

Trp Gln Phe Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-4-carbamoylbutanamido]-3-phenylpropanamido]propanoic acid

C28H34N6O6 (550.2539704000001)


   

Trp Ser Lys Met

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-hydroxypropanamido]hexanamido]-4-(methylsulfanyl)butanoic acid

C25H38N6O6S (550.2573408000001)


   

Trp Ser Met Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-hydroxypropanamido]-4-(methylsulfanyl)butanamido]hexanoic acid

C25H38N6O6S (550.2573408000001)


   

2,5-bis(tert-dodecyldithio)-1,3,4-thiadiazole

2,5-bis(tert-dodecyldithio)-1,3,4-thiadiazole

C26H50N2S5 (550.257738)


   

lead(II) isodecanoate

lead(II) isodecanoate

C20H38O4Pb (550.2536358)


   
   

benzene-1,3-dicarboxylic acid,2,2-dimethylpropane-1,3-diol,2-ethyl-2-(hydroxymethyl)propane-1,3-diol,hexanedioic acid

benzene-1,3-dicarboxylic acid,2,2-dimethylpropane-1,3-diol,2-ethyl-2-(hydroxymethyl)propane-1,3-diol,hexanedioic acid

C25H42O13 (550.2625282)


   

Manumycin A

(2E,4E)-N-[5-hydroxy-5-[(1E,3E,5E)-7-[(2-hydroxy-5-oxocyclopenten-1-yl)amino]-7-oxohepta-1,3,5-trienyl]-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]-2,4,6-trimethyldeca-2,4-dienamide

C31H38N2O7 (550.2678877999999)


D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents D004791 - Enzyme Inhibitors

   
   
   
   
   
   
   

8-Methyl-8-desvinylprotoporphyrin

8-Methyl-8-desvinylprotoporphyrin

C33H34N4O4 (550.2579924)


   

Chisomicine A

Chisomicine A

C32H38O8 (550.2566548)


A natural product found in Chisocheton ceramicus.

   

(R)-2,4,6-Trimethyl-deca-2,4-dienoic acid {(1S,5S,6R)-5-hydroxy-5-[(1E,3E,5E)-6-(2-hydroxy-5-oxo-cyclopent-1-enylcarbamoyl)-hexa-1,3,5-trienyl]-2-oxo-7-oxa-bicyclo[4.1.0]hept-3-en-3-yl}-amide

(R)-2,4,6-Trimethyl-deca-2,4-dienoic acid {(1S,5S,6R)-5-hydroxy-5-[(1E,3E,5E)-6-(2-hydroxy-5-oxo-cyclopent-1-enylcarbamoyl)-hexa-1,3,5-trienyl]-2-oxo-7-oxa-bicyclo[4.1.0]hept-3-en-3-yl}-amide

C31H38N2O7 (550.2678877999999)


   

(2E,4E,6R)-N-[(5S,6R)-5-[(1E,3E,5E)-7-[(2,5-dioxocyclopentyl)amino]-7-oxohepta-1,3,5-trienyl]-5-hydroxy-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]-2,4,6-trimethyldeca-2,4-dienamide

(2E,4E,6R)-N-[(5S,6R)-5-[(1E,3E,5E)-7-[(2,5-dioxocyclopentyl)amino]-7-oxohepta-1,3,5-trienyl]-5-hydroxy-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]-2,4,6-trimethyldeca-2,4-dienamide

C31H38N2O7 (550.2678877999999)


   

[1-[(4E,7E)-deca-4,7-dienoyl]oxy-3-phosphonooxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

[1-[(4E,7E)-deca-4,7-dienoyl]oxy-3-phosphonooxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

C29H43O8P (550.2695408)


   
   
   
   
   
   
   
   
   

(9ar,11as)-1-{2-hydroxy-1-[5-(methoxymethyl)-4-methyl-6-oxo-2,3-dihydropyran-2-yl]ethyl}-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9bh,10h,11h-cyclopenta[a]phenanthrene-7-sulfonic acid

(9ar,11as)-1-{2-hydroxy-1-[5-(methoxymethyl)-4-methyl-6-oxo-2,3-dihydropyran-2-yl]ethyl}-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9bh,10h,11h-cyclopenta[a]phenanthrene-7-sulfonic acid

C29H42O8S (550.2600252000001)


   

(9r,13s,16s,17r,18s)-16-[(1r)-1-hydroxy-1-[(2s)-5-methyl-6-oxo-2,3-dihydropyran-2-yl]ethyl]-8,8,13,17-tetramethyl-6,15-dioxo-7-oxatetracyclo[10.7.0.0³,⁹.0¹³,¹⁷]nonadeca-1(12),2,4,10-tetraen-18-yl acetate

(9r,13s,16s,17r,18s)-16-[(1r)-1-hydroxy-1-[(2s)-5-methyl-6-oxo-2,3-dihydropyran-2-yl]ethyl]-8,8,13,17-tetramethyl-6,15-dioxo-7-oxatetracyclo[10.7.0.0³,⁹.0¹³,¹⁷]nonadeca-1(12),2,4,10-tetraen-18-yl acetate

C32H38O8 (550.2566548)


   

(2e,4e,6r)-n-[(1s,5s,6r)-5-hydroxy-5-[(1e,3e,5e)-6-[(2-hydroxy-5-oxocyclopent-1-en-1-yl)-c-hydroxycarbonimidoyl]hexa-1,3,5-trien-1-yl]-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]-2,4,6-trimethyldeca-2,4-dienimidic acid

(2e,4e,6r)-n-[(1s,5s,6r)-5-hydroxy-5-[(1e,3e,5e)-6-[(2-hydroxy-5-oxocyclopent-1-en-1-yl)-c-hydroxycarbonimidoyl]hexa-1,3,5-trien-1-yl]-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]-2,4,6-trimethyldeca-2,4-dienimidic acid

C31H38N2O7 (550.2678877999999)


   

(1r,2s,5r,6r,13s,14r,16s)-6-(furan-3-yl)-16-(2-methoxy-2-oxoethyl)-1,5,15,15-tetramethyl-8,17-dioxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadeca-9,11-dien-14-yl (2z)-2-methylbut-2-enoate

(1r,2s,5r,6r,13s,14r,16s)-6-(furan-3-yl)-16-(2-methoxy-2-oxoethyl)-1,5,15,15-tetramethyl-8,17-dioxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadeca-9,11-dien-14-yl (2z)-2-methylbut-2-enoate

C32H38O8 (550.2566548)


   

10'-hydroxy-1',6,6',9,10'-pentamethyl-2,5',7-trioxo-4,5,9a,9b-tetrahydro-3ah-4'-oxaspiro[azuleno[4,5-b]furan-3,14'-tetracyclo[10.2.1.0²,¹¹.0³,⁷]pentadecan]-2'(11')-en-8'-yl acetate

10'-hydroxy-1',6,6',9,10'-pentamethyl-2,5',7-trioxo-4,5,9a,9b-tetrahydro-3ah-4'-oxaspiro[azuleno[4,5-b]furan-3,14'-tetracyclo[10.2.1.0²,¹¹.0³,⁷]pentadecan]-2'(11')-en-8'-yl acetate

C32H38O8 (550.2566548)


   

5,5-dimethyl-4-(3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butyl)-3-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)cyclohex-2-en-1-one

5,5-dimethyl-4-(3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butyl)-3-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)cyclohex-2-en-1-one

C25H42O13 (550.2625282)


   

[(1s,4s,5s,6r,9s,10r,11r,12r,14r)-5,6-dihydroxy-7-(hydroxymethyl)-3,11,14-trimethyl-4-{[(2z)-2-methylbut-2-enoyl]oxy}-15-oxotetracyclo[7.5.1.0¹,⁵.0¹⁰,¹²]pentadeca-2,7-dien-11-yl]methyl benzoate

[(1s,4s,5s,6r,9s,10r,11r,12r,14r)-5,6-dihydroxy-7-(hydroxymethyl)-3,11,14-trimethyl-4-{[(2z)-2-methylbut-2-enoyl]oxy}-15-oxotetracyclo[7.5.1.0¹,⁵.0¹⁰,¹²]pentadeca-2,7-dien-11-yl]methyl benzoate

C32H38O8 (550.2566548)


   

(2s)-2-methyl-1-[9,12,14-trihydroxy-13-(2-hydroxy-3-methylbut-3-en-1-yl)-5,5-dimethyl-8-[(2s)-2-methylbutanoyl]-6,17-dioxatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁶]heptadeca-1(10),2(7),3,8,11(16),12,14-heptaen-15-yl]butan-1-one

(2s)-2-methyl-1-[9,12,14-trihydroxy-13-(2-hydroxy-3-methylbut-3-en-1-yl)-5,5-dimethyl-8-[(2s)-2-methylbutanoyl]-6,17-dioxatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁶]heptadeca-1(10),2(7),3,8,11(16),12,14-heptaen-15-yl]butan-1-one

C32H38O8 (550.2566548)


   

(4s,7s,18s,21s)-3,9,17,23-tetrahydroxy-4,5,7,18,19,21-hexamethyl-2,5,8,16,19,22-hexaazatricyclo[22.4.0.0¹⁰,¹⁵]octacosa-1(28),2,8,10,12,14,16,22,24,26-decaene-6,20-dione

(4s,7s,18s,21s)-3,9,17,23-tetrahydroxy-4,5,7,18,19,21-hexamethyl-2,5,8,16,19,22-hexaazatricyclo[22.4.0.0¹⁰,¹⁵]octacosa-1(28),2,8,10,12,14,16,22,24,26-decaene-6,20-dione

C28H34N6O6 (550.2539704000001)


   

(4r)-3-(hydroxymethyl)-5,5-dimethyl-4-[(3r)-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}butyl]cyclohex-2-en-1-one

(4r)-3-(hydroxymethyl)-5,5-dimethyl-4-[(3r)-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}butyl]cyclohex-2-en-1-one

C25H42O13 (550.2625282)


   

[(1s,4s,5r,6r,9s,10r,11r,12r,14r)-4,5,6-trihydroxy-3,11,14-trimethyl-7-({[(2z)-2-methylbut-2-enoyl]oxy}methyl)-15-oxotetracyclo[7.5.1.0¹,⁵.0¹⁰,¹²]pentadeca-2,7-dien-11-yl]methyl benzoate

[(1s,4s,5r,6r,9s,10r,11r,12r,14r)-4,5,6-trihydroxy-3,11,14-trimethyl-7-({[(2z)-2-methylbut-2-enoyl]oxy}methyl)-15-oxotetracyclo[7.5.1.0¹,⁵.0¹⁰,¹²]pentadeca-2,7-dien-11-yl]methyl benzoate

C32H38O8 (550.2566548)


   

(1s,4r,11r,14s,17s,20r)-4-[(2s)-butan-2-yl]-14-[(1r)-1-hydroxyethyl]-17-isopropyl-11,20-dimethyl-19-oxa-6-thia-3,10,13,16,21,22-hexaazatricyclo[16.2.1.1⁵,⁸]docosa-2,5(22),7,9,12,15,18(21)-heptaene-2,9,12,15-tetrol

(1s,4r,11r,14s,17s,20r)-4-[(2s)-butan-2-yl]-14-[(1r)-1-hydroxyethyl]-17-isopropyl-11,20-dimethyl-19-oxa-6-thia-3,10,13,16,21,22-hexaazatricyclo[16.2.1.1⁵,⁸]docosa-2,5(22),7,9,12,15,18(21)-heptaene-2,9,12,15-tetrol

C25H38N6O6S (550.2573408000001)


   

4-hydroxy-3,5,5-trimethyl-4-(3-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}butyl)cyclohex-2-en-1-one

4-hydroxy-3,5,5-trimethyl-4-(3-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}butyl)cyclohex-2-en-1-one

C25H42O13 (550.2625282)


   

2-(hydroxymethyl)-6-{[1,5,5-trimethyl-6-(3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}but-1-en-1-yl)-7-oxabicyclo[4.1.0]heptan-3-yl]oxy}oxane-3,4,5-triol

2-(hydroxymethyl)-6-{[1,5,5-trimethyl-6-(3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}but-1-en-1-yl)-7-oxabicyclo[4.1.0]heptan-3-yl]oxy}oxane-3,4,5-triol

C25H42O13 (550.2625282)


   

3,9,17,23-tetrahydroxy-4,5,7,18,19,21-hexamethyl-2,5,8,16,19,22-hexaazatricyclo[22.4.0.0¹⁰,¹⁵]octacosa-1(28),2,8,10,12,14,16,22,24,26-decaene-6,20-dione

3,9,17,23-tetrahydroxy-4,5,7,18,19,21-hexamethyl-2,5,8,16,19,22-hexaazatricyclo[22.4.0.0¹⁰,¹⁵]octacosa-1(28),2,8,10,12,14,16,22,24,26-decaene-6,20-dione

C28H34N6O6 (550.2539704000001)


   

(2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-{[(1r,3s,6s)-1,5,5-trimethyl-6-[(1e,3s)-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}but-1-en-1-yl]-7-oxabicyclo[4.1.0]heptan-3-yl]oxy}oxane-3,4,5-triol

(2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-{[(1r,3s,6s)-1,5,5-trimethyl-6-[(1e,3s)-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}but-1-en-1-yl]-7-oxabicyclo[4.1.0]heptan-3-yl]oxy}oxane-3,4,5-triol

C25H42O13 (550.2625282)


   

(4,5,6-trihydroxy-3,11,14-trimethyl-7-{[(2-methylbut-2-enoyl)oxy]methyl}-15-oxotetracyclo[7.5.1.0¹,⁵.0¹⁰,¹²]pentadeca-2,7-dien-11-yl)methyl benzoate

(4,5,6-trihydroxy-3,11,14-trimethyl-7-{[(2-methylbut-2-enoyl)oxy]methyl}-15-oxotetracyclo[7.5.1.0¹,⁵.0¹⁰,¹²]pentadeca-2,7-dien-11-yl)methyl benzoate

C32H38O8 (550.2566548)


   

16-[1-hydroxy-1-(5-methyl-6-oxo-2,3-dihydropyran-2-yl)ethyl]-8,8,13,17-tetramethyl-6,15-dioxo-7-oxatetracyclo[10.7.0.0³,⁹.0¹³,¹⁷]nonadeca-1(12),2,4,10-tetraen-18-yl acetate

16-[1-hydroxy-1-(5-methyl-6-oxo-2,3-dihydropyran-2-yl)ethyl]-8,8,13,17-tetramethyl-6,15-dioxo-7-oxatetracyclo[10.7.0.0³,⁹.0¹³,¹⁷]nonadeca-1(12),2,4,10-tetraen-18-yl acetate

C32H38O8 (550.2566548)


   

(1's,3r,3's,3as,6's,7'r,8's,9as,9bs,10'r,12's)-10'-hydroxy-1',6,6',9,10'-pentamethyl-2,5',7-trioxo-4,5,9a,9b-tetrahydro-3ah-4'-oxaspiro[azuleno[4,5-b]furan-3,14'-tetracyclo[10.2.1.0²,¹¹.0³,⁷]pentadecan]-2'(11')-en-8'-yl acetate

(1's,3r,3's,3as,6's,7'r,8's,9as,9bs,10'r,12's)-10'-hydroxy-1',6,6',9,10'-pentamethyl-2,5',7-trioxo-4,5,9a,9b-tetrahydro-3ah-4'-oxaspiro[azuleno[4,5-b]furan-3,14'-tetracyclo[10.2.1.0²,¹¹.0³,⁷]pentadecan]-2'(11')-en-8'-yl acetate

C32H38O8 (550.2566548)


   

14-(1-hydroxyethyl)-17-isopropyl-11,20-dimethyl-4-(sec-butyl)-19-oxa-6-thia-3,10,13,16,21,22-hexaazatricyclo[16.2.1.1⁵,⁸]docosa-2,5(22),7,9,12,15,18(21)-heptaene-2,9,12,15-tetrol

14-(1-hydroxyethyl)-17-isopropyl-11,20-dimethyl-4-(sec-butyl)-19-oxa-6-thia-3,10,13,16,21,22-hexaazatricyclo[16.2.1.1⁵,⁸]docosa-2,5(22),7,9,12,15,18(21)-heptaene-2,9,12,15-tetrol

C25H38N6O6S (550.2573408000001)


   

3-(hydroxymethyl)-5,5-dimethyl-4-(3-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}butyl)cyclohex-2-en-1-one

3-(hydroxymethyl)-5,5-dimethyl-4-(3-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}butyl)cyclohex-2-en-1-one

C25H42O13 (550.2625282)


   

(4s)-4-hydroxy-3,5,5-trimethyl-4-[(3s)-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}butyl]cyclohex-2-en-1-one

(4s)-4-hydroxy-3,5,5-trimethyl-4-[(3s)-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}butyl]cyclohex-2-en-1-one

C25H42O13 (550.2625282)


   

(4s)-5,5-dimethyl-4-[(3r)-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butyl]-3-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)cyclohex-2-en-1-one

(4s)-5,5-dimethyl-4-[(3r)-3-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butyl]-3-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)cyclohex-2-en-1-one

C25H42O13 (550.2625282)


   

(2e,4e,6r)-n-[(1s,5r,6r)-5-hydroxy-5-[(1e,3e,5e)-6-[(2-hydroxy-5-oxocyclopent-1-en-1-yl)-c-hydroxycarbonimidoyl]hexa-1,3,5-trien-1-yl]-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]-2,4,6-trimethyldeca-2,4-dienimidic acid

(2e,4e,6r)-n-[(1s,5r,6r)-5-hydroxy-5-[(1e,3e,5e)-6-[(2-hydroxy-5-oxocyclopent-1-en-1-yl)-c-hydroxycarbonimidoyl]hexa-1,3,5-trien-1-yl]-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]-2,4,6-trimethyldeca-2,4-dienimidic acid

C31H38N2O7 (550.2678877999999)


   

n-[(1r,5s,6r)-5-hydroxy-5-{6-[(2-hydroxy-5-oxocyclopent-1-en-1-yl)-c-hydroxycarbonimidoyl]hexa-1,3,5-trien-1-yl}-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]-2,4,6-trimethyldeca-2,4-dienimidic acid

n-[(1r,5s,6r)-5-hydroxy-5-{6-[(2-hydroxy-5-oxocyclopent-1-en-1-yl)-c-hydroxycarbonimidoyl]hexa-1,3,5-trien-1-yl}-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]-2,4,6-trimethyldeca-2,4-dienimidic acid

C31H38N2O7 (550.2678877999999)


   

[5,6-dihydroxy-7-(hydroxymethyl)-3,11,14-trimethyl-4-[(2-methylbut-2-enoyl)oxy]-15-oxotetracyclo[7.5.1.0¹,⁵.0¹⁰,¹²]pentadeca-2,7-dien-11-yl]methyl benzoate

[5,6-dihydroxy-7-(hydroxymethyl)-3,11,14-trimethyl-4-[(2-methylbut-2-enoyl)oxy]-15-oxotetracyclo[7.5.1.0¹,⁵.0¹⁰,¹²]pentadeca-2,7-dien-11-yl]methyl benzoate

C32H38O8 (550.2566548)